Physician profile
John A Glaspy
NPI 1639104250
$75,180.90
in general payments reported to CMS, 2019-2025
17 companies · $72.32 in 2025
The $72.32 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $13K · 2021: $15K · 2022: $3,780 · 2023: $3,447 · 2024: $12K · 2025: $72.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,893 · Food and Beverage: $532 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,036.00 |
| Travel and Lodging | $1,892.71 |
| Food and Beverage | $531.86 |
| Education | $130.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,299.64 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $11,679.76 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $10,528.00 | 2020-2024 | |
| Acrotech Biopharma INC. | $9,191.42 | 2024 | Ryzneuta |
| Dova Pharmaceuticals | $7,451.82 | 2019 | |
| Seagen INC. | $6,004.99 | 2020-2023 | |
| Daiichi Sankyo INC. | $4,666.86 | 2020-2025 | Datroway |
| Pfizer INC. | $3,956.59 | 2019-2025 | |
| Amgen INC. | $3,780.00 | 2022 | |
| Genentech, INC. | $2,500.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,595.37 | 2019-2020 | |
| Celgene Corporation | $483.25 | 2023 | |
| Array Biopharma INC | $31.28 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Glaspy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.